<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="109122">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01717664</url>
  </required_header>
  <id_info>
    <org_study_id>RHB-104-02</org_study_id>
    <nct_id>NCT01717664</nct_id>
  </id_info>
  <brief_title>Proof of Concept Study of RHB-104 as Add-On Therapy to Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis (RRMS)</brief_title>
  <acronym>CEASE-MS</acronym>
  <official_title>A Phase IIa Proof of Concept Study to Assess the Efficacy and Safety of Fixed Dose Combination RHB-104 as Add-On Therapy to Interferon Beta-1a in Patients Treated for Relapsing Remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedHill Biopharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedHill Biopharma Limited</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that Mycobacterium avium paratuberculosis positive Relapsing
      Remitting MS subjects will have a greater response to Interferon beta-1a therapy plus
      RHB-104 than from Interferon beta-1a alone.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Combined Unique Active lesions</measure>
    <time_frame>Baseline through Wk 24</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <other_outcome>
    <measure>Combined Unique Active lesions</measure>
    <time_frame>Week 24  to Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in cytokine panel</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in cytokine panel</measure>
    <time_frame>Week 24 to Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>MAP status as established by polymerase chain reaction (PCR)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>MAP status as established by polymerase chain reaction (PCR)</measure>
    <time_frame>Week 24 to Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Relapses</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Relapses</measure>
    <time_frame>Week 24 to Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Week 24 to Week 48</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Baseline through Week 24</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Relapsing Remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>RHB-104</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 RHB-104 capsules administered orally BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RHB-104</intervention_name>
    <description>95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
    <arm_group_label>RHB-104</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females aged ≥18 years

          -  Signed fully informed consent provided as per this protocol and willing to comply
             with the required scheduled assessments of the protocol.

          -  Diagnosis of relapsing-remitting multiple sclerosis (McDonald Criteria (2010)) with
             dissemination in time and space.

          -  Currently treated with a stable dose of Rebif®, or Avonex® for a minimum of 3 months
             duration prior to the screening visit.

          -  Active MS with history of at least one flare within the past 12 months or two flares
             in the past 24 months prior to screening.

          -  An Expanded Disability Status Scale (EDSS) of 6.0 or less at the screening visit.

          -  White blood cell count ≥ 3.5x109.

        Exclusion Criteria:

          -  Treatment with any other biological therapies including but not limited to Interferon
             beta-1b, natalizumab, anti-tumor necrosis factor (anti-TNF) biologic agents, or other
             agents intended to reduce TNF ≤ 8 weeks prior to screening or within 5 half-lives of
             agent prior to screening, whichever is longer.

          -  Previous treatment with rifabutin and/or clofazimine.

          -  Oral or parenteral antibiotics in the 4 weeks prior to screening. (Topical
             antibiotics are permitted.)

          -  Use of Methylprednisolone sodium succinate, prednisone, or any other corticosteroid
             during the 30 days prior to screening.

          -  Relapse within 30 days before screening.

          -  Initiation or dose modification of 4-aminopyridine within 60 days of screening.

          -  Use of azathioprine, 6-mercaptopurine (6-MP), methotrexate, cyclosporine or
             mycophenolate (CellCept) within 8 weeks prior to screening.

          -  Use of glatiramer acetate, cyclophosphamide, or plasma exchange within 12 weeks prior
             to screening.

          -  Use of mitoxantrone within one year prior to screening.

          -  Any previous treatment with cladribine, T cell vaccine, or altered peptide ligand.

          -  Previous total body irradiation or total lymphoid irradiation.

          -  Treatment with any medication that has the potential to prolong QT interval or cause
             Torsades de Pointes within 7 days of screening, including: Cisapride,
             pimozide,astemizole, terfenadine, ergotamine, dihydroergotamine, quinidine,
             procainamide, disopyramide, amiodarone, sotalol, ibutilde, dofetilide and
             dronedarone.

          -  Treatment with any medication that is a CYP3A4 substrate, including: colchicine,
             simvastatin, lovastatin, atorvastatin, verapamil, amlodipine, diltiazem, sildenafil,
             tadalafil, vardenafil, fluconazole and midazolam.

          -  Treatment with any contraindicated medications as listed in the prescriber
             information for each respective antibiotic found in RHB-104. (See Investigator
             Brochure (IB))

          -  Serious adverse reaction or hypersensitivity to the study drug or any medications
             related to the study drug.

          -  Clinically significant abnormalities of hematology or biochemistry, including but not
             limited to, elevations greater than 2 times the upper limit of normal of Aspartate
             Aminotransferase (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase or
             creatinine clearance less than 60 ml/min at screening.

          -  Serum potassium, magnesium or calcium outside the normal reference range.

          -  Positive stool results for C. difficile.

          -  A positive serology for Hepatitis B, Hepatitis C or HIV at screening.

          -  History of the following diseases:

               -  Atypical mycobacterial infections (other than MAP)

               -  Active tuberculosis requiring treatment in the past 3 years

               -  Positive quantiFERON test

          -  Currently diagnosed or history of uveitis confirmed by either an ophthalmologist or
             optometrist.

          -  Any evidence of any other significant hematological, hepatic, renal, cardiac,
             pulmonary, metabolic, thyroid, neurological or psychiatric disease that might
             interfere with the subject's ability to safely enter and or complete the study
             requirements.

          -  Males who do not use barrier contraceptive methods (i.e. condom) with spermicidal
             foam/gel/cream/suppository or have not had a vasectomy.

          -  Females who are not post-menopausal for at least the previous 12 months, have not had
             a hysterectomy or tubal ligation or females of child bearing potential who:

               1. have a positive pregnancy test

               2. are lactating

               3. have not used oral contraceptives for at least three continuous months prior to
                  date of screening

               4. do not use nonhormonal contraceptive methods such as barrier (i.e. diaphragm,
                  cervical cap, and contraceptive sponge) with spermicidal
                  foam/gel/cream/suppository, or intrauterine device (IUD) unless their partner(s)
                  use barrier contraceptive methods with spermicidal foam/gel/cream/suppository or
                  have had a vasectomy

          -  Refusal to sign the study informed consent form.

          -  Inability to adequately communicate with the investigator or their respective
             designee and/or comply with the requirements of the entire study.

          -  History of drug or alcohol abuse.

          -  Participation in any experimental drug protocol within 12 weeks of date of screening.

          -  Cardiac pacemaker or any other type of metal implant or any other contraindication
             for MRI (including known allergy to gadolinium).

          -  Corrected QT interval (QTc)&gt;440ms, bundle branch block, or major T wave abnormalities
             that make the assessment of the QT impossible.

          -  History of unstable cardiac syndromes including unstable angina, coronary artery
             bypass graft, myocardial infarction or coronary stenting within 2 months; New York
             Heart Association Class 3-4 congestive heart failure; history of ventricular
             tachycardia, ventricular fibrillation, personal or family history of sudden death,
             Long QT Syndrome, or Torsade de Pointes; heart rate &lt;50 beats per minute; taking any
             Class 1 or Class 3 antiarrhythmic medications or medicines known to prolong the QT
             interval or be associated with Torsade de Pointes.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ira N Kalfus, MD</last_name>
    <role>Study Director</role>
    <affiliation>RedHill Biopharma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Radi Shahien, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziv Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RedHill Biopharma</last_name>
    <phone>+972-(0)3-541-3131</phone>
    <email>info@redhillbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ira N Kalfus, MD</last_name>
    <phone>+1-917-817-7517</phone>
    <email>ira@redhillbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RedHill MS Clinical Trial Site 002</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oren Weintraub</last_name>
      <email>orenw@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Arnon Karni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>RedHill MS Clinical Trials Site 001</name>
      <address>
        <city>Zefat (Safed)</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wedad Nachle</last_name>
      <email>wadad.n@ziv.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Radi Shahien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 20, 2014</lastchanged_date>
  <firstreceived_date>October 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing Remitting Multiple Sclerosis</keyword>
  <keyword>MAP</keyword>
  <keyword>antibiotic</keyword>
  <keyword>Interferon beta 1-a</keyword>
  <keyword>MS</keyword>
  <keyword>MRI</keyword>
  <keyword>EDSS</keyword>
  <keyword>relapse rate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon beta 1a</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
